Zobrazeno 1 - 5
of 5
pro vyhledávání: '"James P. Allison"'
Autor:
Pavlos Msaouel, Sangeeta Goswami, Peter F. Thall, Xuemei Wang, Ying Yuan, Eric Jonasch, Jianjun Gao, Matthew T. Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda L. Tam, Kamran Ahrar, Priya Rao, Kanishka Sircar, Lorenzo Cohen, Sreyashi Basu, Fei Duan, Sonali Jindal, Yuwei Zhang, Hong Chen, Shalini S. Yadav, Ronald Shazer, Hirak Der-Torossian, James P. Allison, Padmanee Sharma, Nizar M. Tannir
Publikováno v:
Science Translational Medicine. 14
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitrava
Autor:
Liangwen Xiong, Wenbin Liu, Matthew D. Galsky, Abdel Saci, Péter Szabó, Baoxiang Guan, Sangeeta Goswami, Jorge Blando, Seanu Meena Natarajan, Sreyashi Basu, Padmanee Sharma, Yulong Chen, Jan Zhang, Shalini S. Yadav, Swetha Anandhan, James P. Allison
Publikováno v:
Science Translational Medicine. 12
Immune checkpoint therapy (ICT) can produce durable antitumor responses in metastatic urothelial carcinoma (mUCC); however, the responses are not universal. Despite multiple approvals of ICT in mUCC, we lack predictive biomarkers to guide patient sel
Autor:
Jacob Austin-Breneman, Qing Chang, Alexandre Reuben, Mariana Petaccia de Macedo, P. Andrew Futreal, Alexander J. Lazar, Vancheswaran Gopalakrishnan, Padmanee Sharma, Victor G. Prieto, Rodabe N. Amaria, Khalida Wani, Jeffrey E. Gershenwald, Jason Roszik, Sangeetha M. Reddy, Patrick Hwu, James P. Allison, Peter A. Prieto, Pei Ling Chen, Wen-Jen Hwu, Jianhua Hu, Hong Jiang, Latasha Little, Jennifer A. Wargo, Eveline Chen, Hussein Abdul-Hassan Tawbi, John P. Miller, Jianhua Zhang, Christine N. Spencer, Feng Wang, Michael A. Davies, Whijae Roh, Scott E. Woodman, Curtis Gumbs, Michael T. Tetzlaff, Sapna Pradyuman Patel, Adi Diab, Zachary A. Cooper, Wei Shen Chen, Lynda Chin, Isabella C. Glitza
Publikováno v:
Science Translational Medicine. 9
Immune checkpoint blockade produces clinical benefit in many patients. However better biomarkers of response are still needed, and mechanisms of resistance remain incompletely understood. To address this, we recently studied a cohort of melanoma pati
Autor:
Sumit K. Subudhi, Taha Merghoub, Rikke B. Holmgaard, Mena Mansour, Peter Palese, James P. Allison, Joon Seok Park, Dmitriy Zamarin, Jedd D. Wolchok
Publikováno v:
Science Translational Medicine. 6
Preexisting lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers. Recent studies also suggest that lymphocytic responses may identify patients more likely to benefit from therapies targeting immun
Autor:
Sharma P; Padmanee Sharma is a professor of Genitourinary Medical Oncology and Immunology, the scientific director of the Immunotherapy Platform, and the director of Scientific Programs of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Email: padsharma@mdanderson.org.; James P. Allison is the chair of Immunology, the executive director of the Immunotherapy Platform, the deputy director for Applied Research of Genitourinary Cancers, and the director of the James P. Allison Institute at the University of Texas MD Anderson Cancer Center, Houston, TX, USA. He is a CPRIT Distinguished Scholar in Cancer Research. Email: jallison@mdanderson.org., Allison JP; Padmanee Sharma is a professor of Genitourinary Medical Oncology and Immunology, the scientific director of the Immunotherapy Platform, and the director of Scientific Programs of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Email: padsharma@mdanderson.org.; James P. Allison is the chair of Immunology, the executive director of the Immunotherapy Platform, the deputy director for Applied Research of Genitourinary Cancers, and the director of the James P. Allison Institute at the University of Texas MD Anderson Cancer Center, Houston, TX, USA. He is a CPRIT Distinguished Scholar in Cancer Research. Email: jallison@mdanderson.org.
Publikováno v:
Science translational medicine [Sci Transl Med] 2022 Nov 09; Vol. 14 (670), pp. eadf2947. Date of Electronic Publication: 2022 Nov 09.